The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.

Petra DeegenOliver ThomasOlivier Nolan-StevauxShyun LiJoachim WahlPamela BognerFamke AeffnerMatthias FriedrichMichael Z LiaoKatja MatthesDoris RauBenno RattelTobias RaumPeter KuferAngela CoxonJulie M Bailis

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

The preclinical characterization of AMG 160 highlights its potent antitumor activity in vitro and in vivo, and its potential for use with known diagnostic or therapeutic agents in mCRPC. These data support the ongoing clinical evaluation of AMG 160 in patients with mCRPC.See related commentary by Kamat et al., p. 2675.

Keyphrases

cell therapy
pet ct
squamous cell carcinoma
small cell lung cancer
anti inflammatory
electronic health record
pet imaging
cancer therapy
stem cells
bone marrow
deep learning
replacement therapy